Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma

Affiliations

¹ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hultcram@mskcc.org.
³ Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. hultcram@mskcc.org.
⁴ Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Center for Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ University of Milan, Department of Oncology and Onco-Hematology, Milan, Italy.
⁸ Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Hematology, Milan, Italy.
⁹ Hematopathology Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Epidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. zhangy1@mskcc.org.
¹² Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. landgrec@mskcc.org.

^# Contributed equally.

Published Erratum

Venkata Yellapantula et al. Blood Cancer J. 2020.

. 2020 Jan 30;10(1):11.

doi: 10.1038/s41408-020-0279-4.

¹ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hultcram@mskcc.org.
³ Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. hultcram@mskcc.org.
⁴ Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Center for Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ University of Milan, Department of Oncology and Onco-Hematology, Milan, Italy.
⁸ Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Hematology, Milan, Italy.
⁹ Hematopathology Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Epidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. zhangy1@mskcc.org.
¹² Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. landgrec@mskcc.org.

^# Contributed equally.

Abstract

A correction to this paper has been published and can be accessed via a link at the top of the paper.

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O. Yellapantula V, et al. Blood Cancer J. 2019 Dec 11;9(12):101. doi: 10.1038/s41408-019-0264-y. Blood Cancer J. 2019. PMID: 31827071 Free PMC article.